{"entity":{"id":"thierry-facon","kind":"person","name":"Thierry Facon","aka":[],"tldr":"Led MAIA, which made daratumumab-lenalidomide-dexamethasone the standard for older patients with myeloma.","summary":"Thierry Facon (Lille) was principal investigator of MAIA, the trial showing daratumumab plus lenalidomide-dexamethasone dramatically improves progression-free and overall survival in transplant-ineligible newly diagnosed myeloma, with median survival now beyond seven years, and of FIRST, which established continuous lenalidomide-dexamethasone in this population. He led the IFM frailty score work and co-leads the IMROZ isatuximab trial.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Facon%20T%5BAuthor%5D%20myeloma%20daratumumab%20MAIA"}],"tags":["myeloma","older-patients","trialist"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["cd38"],"drugs":[],"companies":[],"institutions":["chu-lille"],"pathways":[],"terms":[],"trials":["imroz"],"people":[],"bottlenecks":[],"keyPapers":["paper-maia-daratumumab-rd-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology, Lille University Hospital (CHU Lille)","institutionId":"chu-lille","specialisms":["Multiple myeloma","Older and transplant-ineligible patients","Daratumumab","Frailty"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Facon%20T%5BAuthor%5D%20myeloma%20daratumumab%20MAIA"}],"papers":[{"title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma (MAIA)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1817249"},{"title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma (FIRST)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1402551"}]},"route":"/people/thierry-facon/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"}],"institution":[{"id":"chu-lille","kind":"institution","name":"Lille University Hospital (CHU de Lille)","route":"/institutions/chu-lille/"}],"trial":[{"id":"imroz","kind":"trial","name":"IMROZ","route":"/trials/imroz/"},{"id":"maia","kind":"trial","name":"MAIA","route":"/trials/maia/"}],"paper":[{"id":"paper-maia-daratumumab-rd-nejm-2019","kind":"paper","name":"MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant","route":"/key-papers/paper-maia-daratumumab-rd-nejm-2019/"}]}}